Direct-acting antivirals (DAAs) are antiviral medications that specifically inhibit proteins of the hepatitis C virus (HCV), thereby preventing its replication.
In droplet infection, pathogens are spread via larger liquid droplets, such as those produced when coughing, that come into contact with another person’s mucous membranes.